Stocks · Health care · Biological Products, (No Diagnostic Substances)

Lexeo Therapeutics, Inc.

LXEO Clue Score11
United States Fiscal year ends December CIK 0001907108 Results filed 12 Aug 2026

What the insiders did Net buying

By person

13 insiders · 56 transactions
2.9×

R. Nolan Townsend holds only 2.9 times base salary in stock. $1.86M of shares against $632.70K in salary for 2025.

Salary from the company's own proxy. The shares are what R. Nolan Townsend last reported holding, valued at $4.96, the price Common Stock was last bought or sold at on the open market here, on 18 Aug 2026.

Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Longitude Capital Partners IV, LLC entity
10% owner
$5.00M (1)
—
+$5.00M
2,567,100
$12.73M
—
Omega Fund VI, L.P. entity
10% owner
$5.00M (1)
—
+$5.00M
2,157,623
$10.70M
—
Invest A/S Lundbeckfond
10% owner
$2.50M (1)
—
+$2.50M
1,835,959
$9.10M
—
Richard Nolan Townsend
Chief Executive Officer
—
$1.96M (23) scheduled
−$1.96M
376,778
$1.87M
+193.1%
Paula H Cholmondeley
Director
$104.85K (1)
—
+$104.85K
30,627
$151.82K
+96.0%
Narinder Pal Bhalla
Chief Medical Officer
—
$98.59K (1)
−$98.59K
84,908
$420.90K
—
Jose Manuel Otero
Chief Operating Officer
—
$92.16K (8)
−$92.16K
138,288
$685.51K
—
Eric Adler
Chief Medical Officer
—
$50.81K (6)
−$50.81K
72,646
$360.11K
—
Jenny Robertson
Chief Legal Officer
—
$49.87K (6)
−$49.87K
68,381
$338.97K
—
Tai Sandi See
Chief Development Officer
—
$47.70K (6)
−$47.70K
65,476
$324.57K
+293.8%
Louis Edward Tamayo
Chief Financial Officer
—
$41.04K (2)
−$41.04K
92,907
$460.55K
—
Kyle Rasbach
Chief Financial Officer
—
—
—
40,875
$202.62K
—
Paul McCormac
Chief Technical Officer
—
—
—
17,349
$86.00K
+22.5%

No percentages here. This company's share count has moved by a factor of 2.5 over the window, from 33,196,997 to 82,046,255 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.